Pipeline Watch: Phase III Progress With Biosimilar Adalimumab And Trastuzumab
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
You may also be interested in...
J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
Plunging biopharma company stock values and declining IPO activity have contributed to a more difficult financing environment, but money is still available for public and private drug developers whose products provide value in the eyes of patients and payers.
Women fill many roles in biopharma companies, but relatively few are in leadership positions. Executives who spoke with Scrip in a roundtable discussion during the J.P. Morgan Healthcare Conference earlier this month noted the disconnect, but saw some hope for improved gender diversity in the future.